Editor's Note
The data from this mouse and rat study showed that oral administration of a succulent species  Hoodia parviflora  N.E. Br. (HP) exerts an anti-inflammatory effect that improves insulin resistance, alleviating hepatic steatosis and associated liver injury. The authors conclude that HP-derived extract is associated with alleviation of insulin resistance, improved hepatic steatosis, and improved liver injury. The data supported the potential liver protector effects of these extracts.
December 2019
Journal of Medicinal Food
DOI: https://doi.org/10.1089/jmf.2019.0093

Metabolic syndrome is recognized as a proinflammatory condition leading to hepatic steatosis and nonalcoholic steatohepatitis (NASH). We tested the effects of a succulent species Hoodia parviflora N.E. Br., of the genus Hoodia sweet ex Dence, on animal models of NASH and insulin resistance ( ob/ob mouse and the sand rat Psammomys obesus ). IL6 secretion was evaluated by ELISA and hepatic signal transducer and activator of transcription 3 by Western blot. We followed liver enzymes, weight, glucose, hepatic histology, hepatic triglycerides (TGs), and total fat and serum insulin. Oral administration of extracts derived from H. parviflora alleviated the insulin resistance manifested by improved glucose tolerance tests. Treatment alleviated the liver injury noted by a decrease in liver enzyme levels, improved intrahepatic TG content, total hepatic fat, and improved hepatic histology. Similarly, treatment with H. parviflora reduced hepatic inflammation in mice with Concanavalin A-induced hepatitis. These effects were independent of food consumption and weight. H. parviflora was associated with alleviated insulin resistance, hepatic steatosis, and liver injury. The data support its use as a liver protector.

2020 Annual Fund Sponsors: